Why Is Kalaris Therapeutics Stock Gaining Friday?
Kalaris Therapeutics (NASDAQ: KLRS) stock jumps 18% after releasing expanded Phase 1a data for its AMD treatment, TH103.
Why It Matters
Kalaris shared new test results showing their eye-medicine experiment is going well, and traders got excited about it. When companies show their medicine is working safely, people often want to own a piece of the company, so the stock price jumped up.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.